首页 > 市场调查报告书 > 医疗设备

体外诊断生技设备 POC诊断

市场调查报告书

商品编码

1882182

全球照护现场分子诊断市场

Point of Care (POC) Molecular Diagnostics

出版日期: 2025年12月03日 | 出版商:

Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 英文 409 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

全球照护现场分子诊断市场预计2030年将达到88亿美元

全球照护现场分子诊断（POC）市场规模预计在2024年达到42亿美元，到2030年将达到88亿美元，在分析期间（2024-2030年）内复合年增长率（CAGR）为12.9%。本报告分析的感染疾病应用领域预计复合年增长率为12.9%，到分析期末将达62亿美元。肿瘤应用领域预计在分析期间内复合年增长率为14.6%。

美国市场规模估计为17亿美元，而中国市场预计将以15.4%的复合年增长率成长。

预计到2024年，美国照护现场将达17亿美元。作为世界第二大经济体，中国预计在分析期（2024-2030年）内将以15.4%的复合年增长率成长，到2030年市场规模将达到10亿美元。其他值得关注的区域市场包括日本和加拿大，预计在分析期内将分别以10.7%和12.2%的复合年增长率成长。在欧洲，德国预计将以约12.1%的复合年增长率成长。

全球照护现场分子诊断市场—关键趋势与驱动因素概述

即时分子诊断（POC）是一种在患者照护地点附近而非中心检查室进行分子诊断检测的技术。该技术透过核酸分析实现疾病的快速检测，可在数分钟至数小时内提供结果，而非数天。其照护现场是为医护人员提供及时的信息，从而支持他们即时做出临床决策并启动治疗。 POC分子诊断设备通常携带式或手持，设计易于使用，只需极少的培训即可上手，并且与传统的检查室检测相比，操作步骤更少。这种快速且方便的检测方式在感染疾病、遗传性疾病和癌症等医疗保健应用中尤其重要。

即时分子诊断的效用在全球医疗机构中日益凸显，尤其是在急诊室、加护病房以及传统检测设施匮乏的偏远地区。在感染疾病管理方面，例如流感、新冠肺炎和其他病毒感染疾病的快速诊断，即时检测能够迅速做出隔离决策，并显着降低感染传播。此外，在肿瘤学等领域，即时分子诊断能够即时评估肿瘤标记和基因突变，从而在诊疗现场直接指南个人化治疗策略。其在药房和社区诊所等非医院环境中的适用性进一步扩大了其覆盖范围和影响力，使更多人群能够获得诊断服务。

即时分子诊断市场的成长受多种因素驱动。技术进步提高了即时检测设备的准确性、速度和易用性，这是市场扩张的主要驱动力。多重检测技术的不断发展，使得在同一设备上同时进行多种检测成为可能，也显着提升了即时检测的效用和吸引力。此外，全球感染疾病负担日益加重，以及疫情管理中对快速诊断方法的需求不断增长，凸显了即时检测的关键作用。经济因素，例如缩短住院时间和减少对中心实验室依赖所带来的成本节约，也在推动即时检测在各种医疗机构中的应用。消费行为，特别是对即时医疗服务日益增长的期望以及对个人化医疗的认知不断提高，也进一步推动了对这些创新诊断解决方案的需求。

部分：

依技术（基于PCR、基于基因定序、基于杂合反应、基于微阵列）、按应用（感染疾病、肿瘤学、血液学、其他应用）、按最终用途（分散式检查实验室、医院、居家医疗、辅助生活设施、其他最终用途）分类

受访公司范例

Bayer AG
Danaher Corporation
DiaSorin SpA
Biocartis NV
Maxim Biomedical, Inc.
AccuBioTech Co., Ltd.
Abacus Diagnostica Oy
genedrive plc
Molbio Diagnostics Pvt. Ltd.
Mesa Biotech, Inc.
Binx Health
Credo Diagnostics Biomedical Pte. Ltd
Genestat Molecular Diagnostics, LLC
Alveo Technologies
ADOR Diagnostics

人工智慧集成

我们正在利用检验的专家内容和人工智慧工具，改变您分析市场和竞争情报的方式。

Market Glass, Inc. 并没有采用咨询 LLM 或产业专用的SLM 的典型方法，而是建立了一个由世界各地领域专家精心策划的内容库，其中包括视讯文字稿、部落格、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

在最新发布的报告中，Market Glass, Inc. 将关税对地理市场的影响纳入考量，并根据公司总部所在国、製造地以及进出口（成品和OEM产品）情况，预测企业竞争格局的变化。这种复杂多变的市场现实将对竞争对手产生多方面的影响，包括销货成本增加、盈利下降和供应链重组，同时也会影响微观和宏观市场动态。

The global market for Point of Care (POC) Molecular Diagnostics estimated at US$4.2 Billion in the year 2024, is expected to reach US$8.8 Billion by 2030, growing at a CAGR of 12.9% over the analysis period 2024-2030. Infectious Diseases Application, one of the segments analyzed in the report, is expected to record a 12.9% CAGR and reach US$6.2 Billion by the end of the analysis period. Growth in the Oncology Application segment is estimated at 14.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.7 Billion While China is Forecast to Grow at 15.4% CAGR

The Point of Care (POC) Molecular Diagnostics market in the U.S. is estimated at US$1.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.0 Billion by the year 2030 trailing a CAGR of 15.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.7% and 12.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.1% CAGR.

Global Point of Care (POC) Molecular Diagnostics Market - Key Trends and Drivers Summarized

Point of Care (POC) molecular diagnostics involves the performance of molecular diagnostic tests near the site of patient care rather than in a central laboratory. This technology enables the rapid detection of diseases through nucleic acid analysis, providing results within minutes or hours rather than days. The aim is to deliver timely information to healthcare providers, enabling immediate clinical decision-making and treatment initiation. POC molecular diagnostic devices are typically portable or handheld, designed to be easy to use with minimal training, and require fewer operational steps compared to traditional lab-based tests. This rapid and convenient form of testing is particularly valuable for managing infectious diseases, genetic conditions, and cancer, among other medical applications.

The utility of POC molecular diagnostics has become increasingly evident in healthcare settings around the world, particularly in emergency rooms, intensive care units, and remote areas where access to conventional lab facilities may be limited. In infectious disease management, such as the timely diagnosis of influenza, COVID-19, and other viral infections, POC testing can drastically reduce the spread of infections by enabling quick isolation decisions. Additionally, in settings like oncology, POC molecular diagnostics facilitate the real-time assessment of tumor markers and mutations, which can guide personalized treatment strategies directly at the point of care. The technology's adaptability to non-hospital environments, such as pharmacies and community clinics, further extends its reach and impact, making diagnostic services accessible to a broader population.

The growth in the POC molecular diagnostics market is driven by several factors. Technological advancements that enhance the accuracy, speed, and user-friendliness of POC devices are major contributors to market expansion. The ongoing development of multiplexing capabilities, where multiple tests are conducted at the same time on the same device, also significantly boosts the utility and attractiveness of POC diagnostics. Furthermore, the increasing global burden of infectious diseases and the rising demand for rapid diagnostic methods in pandemic management highlight the critical role of POC testing. Economic factors, including cost savings associated with reduced hospital stays and less reliance on centralized laboratory facilities, encourage the adoption of POC diagnostics across various healthcare settings. Consumer behavior, particularly the growing expectation for immediate healthcare delivery and the rising awareness of personalized medicine, further propels the demand for these innovative diagnostic solutions.

SCOPE OF STUDY:

The report analyzes the Point of Care (POC) Molecular Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (PCR-based, Genetic Sequencing-based, Hybridization-based, Microarray-based); Application (Infectious Diseases, Oncology, Hematology, Other Applications); End-Use (Decentralized Labs, Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses)

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Australia; India; South Korea; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Iran; Israel; Saudi Arabia; UAE; Rest of Middle East; Africa.

Select Competitors (Total 64 Featured) -

Bayer AG
Danaher Corporation
DiaSorin SpA
Biocartis NV
Maxim Biomedical, Inc.
AccuBioTech Co., Ltd.
Abacus Diagnostica Oy
genedrive plc
Molbio Diagnostics Pvt. Ltd.
Mesa Biotech, Inc.
Binx Health
Credo Diagnostics Biomedical Pte. Ltd
Genestat Molecular Diagnostics, LLC
Alveo Technologies
ADOR Diagnostics

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
- Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
- How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
- Point of Care (POC) Molecular Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
- Molecular Diagnostics: Leveraging Molecular Technologies to Monitor Human Diseases
- Types of Molecular Diagnostics Tests
- An Introduction to Point of Care (POC) Molecular Diagnostics
- Molecular Testing Mechanisms
- Molecular Vs Non-Molecular POCT
- Global Market Prospects & Outlook
- PCR Technology Leads the MDx Market
- Infectious Diseases: The Largest Application Market
- Reagents and Kits Dominate the Molecular Diagnostics Market
- Developing Countries Present Strong Growth Prospects
- Competition
- Recent Market Activity
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
- Rising Demand for Point of Care Diagnostics Augurs Well for Molecular POC Diagnostics Market
- Emphasis on Decentralized Diagnostics Presents Opportunity for POC Testing
- Growing Prevalence of Infectious Diseases Spurs Need for POC Molecular Diagnostics
- Infectious Diseases Remain Major Cause of Death in Under Developed Regions: Breakdown of Leading Causes of Death in Sub-Saharan Africa (in %)
- Infectious Diseases Related Mortality High Among Children Below 5 Years: Breakdown of Leading Causes of Death in Children Below 5 Years (in %)
- PCR Plays a Vital Role in the Diagnosis of Infectious Diseases
- Rising Prevalence of Respiratory Infections to Drive Need for POC Molecular Diagnostics
- Global Number of Deaths Caused Due to Communicable Diseases (In 000s)
- Rise in Pollution Levels Trigger Increase in Respiratory Diseases, Driving Market Opportunities
- Percentage Share Breakdown of Global Deaths Linked to Air Pollution
- Air Pollution Levels (PM2.5 Concentration (μg/m3) for Major Countries Worldwide for 2023
- Rising Cancer Incidence Drives Focus onto POC Molecular Diagnostics
- Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
- Rising Incidence of Hospital Acquired Infections (HAIs) Propels Demand for POC Molecular Diagnostics
- Sustained Threat of HIV and Sexually Transmitted Diseases Amplify Need for POC Molecular Diagnostics
- Rapid HIV Tests: A New Age Diagnostic Weapon against the Killer Disease
- Home HIV Testing Emerges as a Lucrative Option
- Molecular Tests Gaining Prominence in GC/Chlamydia Testing Market
- Molecular Diagnostics Opens New Avenues in Viral Hepatitis Testing
- Hepatitis B Prevalence Worldwide by Region
- Demand Continues to Surge for CLIA-Waived Molecular POC Tests
- Advancements in POC for Molecular Diagnostics to Drive Market Growth
- Nanotechnology Facilitates Development of for POC Molecular Diagnostics
- Healthcare Needs of the World's Aging Population: Potential Opportunity in Store
- Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
- Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
- Increase in Healthcare Spending in Emerging Markets to Propel Demand for POC Molecular Diagnostics
- Elderly Healthcare Expenditure as a % of GDP for 1970, 2010 and 2050
- Challenges Facing POC Molecular Diagnostics Market
4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Recent Past, Current & Future Analysis for PCR-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 2: World Historic Review for PCR-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 3: World 15-Year Perspective for PCR-based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 4: World Recent Past, Current & Future Analysis for Genetic Sequencing-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 5: World Historic Review for Genetic Sequencing-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 6: World 15-Year Perspective for Genetic Sequencing-based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 7: World Recent Past, Current & Future Analysis for Hybridization-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 8: World Historic Review for Hybridization-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 9: World 15-Year Perspective for Hybridization-based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 10: World Recent Past, Current & Future Analysis for Microarray-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 11: World Historic Review for Microarray-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 12: World 15-Year Perspective for Microarray-based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 13: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 14: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 15: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 16: World Recent Past, Current & Future Analysis for Home Care by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 17: World Historic Review for Home Care by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 18: World 15-Year Perspective for Home Care by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 19: World Recent Past, Current & Future Analysis for Assisted Living Healthcare Facilities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 20: World Historic Review for Assisted Living Healthcare Facilities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 21: World 15-Year Perspective for Assisted Living Healthcare Facilities by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 22: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 23: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 24: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 25: World Recent Past, Current & Future Analysis for Decentralized Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 26: World Historic Review for Decentralized Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 27: World 15-Year Perspective for Decentralized Labs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 28: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 29: World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 30: World 15-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 31: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 32: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 33: World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 34: World Recent Past, Current & Future Analysis for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 35: World Historic Review for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 36: World 15-Year Perspective for Hematology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 37: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 38: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 39: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 40: World Point of Care (POC) Molecular Diagnostics Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
- TABLE 41: World Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 42: World Historic Review for Point of Care (POC) Molecular Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 43: World 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

UNITED STATES
- Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
- TABLE 44: USA Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 45: USA Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 46: USA 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2015, 2025 & 2030
- TABLE 47: USA Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 48: USA Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 49: USA 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2015, 2025 & 2030
- TABLE 50: USA Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 51: USA Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 52: USA 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2015, 2025 & 2030
CANADA
- TABLE 53: Canada Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 54: Canada Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 55: Canada 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2015, 2025 & 2030
- TABLE 56: Canada Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 57: Canada Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 58: Canada 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2015, 2025 & 2030
- TABLE 59: Canada Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 60: Canada Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 61: Canada 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2015, 2025 & 2030
JAPAN
- Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
- TABLE 62: Japan Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 63: Japan Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 64: Japan 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2015, 2025 & 2030
- TABLE 65: Japan Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 66: Japan Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 67: Japan 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2015, 2025 & 2030
- TABLE 68: Japan Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 69: Japan Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 70: Japan 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2015, 2025 & 2030
CHINA
- Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
- TABLE 71: China Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 72: China Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 73: China 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2015, 2025 & 2030
- TABLE 74: China Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 75: China Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 76: China 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2015, 2025 & 2030
- TABLE 77: China Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 78: China Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 79: China 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2015, 2025 & 2030
EUROPE
- Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
- TABLE 80: Europe Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 81: Europe Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 82: Europe 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2015, 2025 & 2030
- TABLE 83: Europe Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 84: Europe Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 85: Europe 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2015, 2025 & 2030
- TABLE 86: Europe Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 87: Europe Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 88: Europe 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2015, 2025 & 2030
- TABLE 89: Europe Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 90: Europe Historic Review for Point of Care (POC) Molecular Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 91: Europe 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
FRANCE
- Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
- TABLE 92: France Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 93: France Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 94: France 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2015, 2025 & 2030
- TABLE 95: France Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 96: France Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 97: France 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2015, 2025 & 2030
- TABLE 98: France Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 99: France Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 100: France 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2015, 2025 & 2030
GERMANY
- Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
- TABLE 101: Germany Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 102: Germany Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 103: Germany 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2015, 2025 & 2030
- TABLE 104: Germany Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 105: Germany Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 106: Germany 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2015, 2025 & 2030
- TABLE 107: Germany Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 108: Germany Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 109: Germany 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2015, 2025 & 2030
ITALY
- TABLE 110: Italy Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 111: Italy Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 112: Italy 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2015, 2025 & 2030
- TABLE 113: Italy Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 114: Italy Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 115: Italy 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2015, 2025 & 2030
- TABLE 116: Italy Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 117: Italy Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 118: Italy 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2015, 2025 & 2030
UNITED KINGDOM
- Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
- TABLE 119: UK Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 120: UK Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 121: UK 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2015, 2025 & 2030
- TABLE 122: UK Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 123: UK Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 124: UK 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2015, 2025 & 2030
- TABLE 125: UK Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 126: UK Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 127: UK 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2015, 2025 & 2030
SPAIN
- TABLE 128: Spain Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 129: Spain Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 130: Spain 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2015, 2025 & 2030
- TABLE 131: Spain Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 132: Spain Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 133: Spain 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2015, 2025 & 2030
- TABLE 134: Spain Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 135: Spain Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 136: Spain 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2015, 2025 & 2030
RUSSIA
- TABLE 137: Russia Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 138: Russia Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 139: Russia 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2015, 2025 & 2030
- TABLE 140: Russia Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 141: Russia Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 142: Russia 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2015, 2025 & 2030
- TABLE 143: Russia Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 144: Russia Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 145: Russia 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2015, 2025 & 2030
REST OF EUROPE
- TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 147: Rest of Europe Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 148: Rest of Europe 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2015, 2025 & 2030
- TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 150: Rest of Europe Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 151: Rest of Europe 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2015, 2025 & 2030
- TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 153: Rest of Europe Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 154: Rest of Europe 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2015, 2025 & 2030
ASIA-PACIFIC
- Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
- TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 156: Asia-Pacific Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 157: Asia-Pacific 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2015, 2025 & 2030
- TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 159: Asia-Pacific Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 160: Asia-Pacific 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2015, 2025 & 2030
- TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 162: Asia-Pacific Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 163: Asia-Pacific 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2015, 2025 & 2030
- TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 165: Asia-Pacific Historic Review for Point of Care (POC) Molecular Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 166: Asia-Pacific 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
AUSTRALIA
- Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
- TABLE 167: Australia Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 168: Australia Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 169: Australia 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2015, 2025 & 2030
- TABLE 170: Australia Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 171: Australia Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 172: Australia 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2015, 2025 & 2030
- TABLE 173: Australia Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 174: Australia Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 175: Australia 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2015, 2025 & 2030
INDIA
- Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
- TABLE 176: India Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 177: India Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 178: India 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2015, 2025 & 2030
- TABLE 179: India Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 180: India Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 181: India 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2015, 2025 & 2030
- TABLE 182: India Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 183: India Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 184: India 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2015, 2025 & 2030
SOUTH KOREA
- TABLE 185: South Korea Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 186: South Korea Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 187: South Korea 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2015, 2025 & 2030
- TABLE 188: South Korea Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 189: South Korea Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 190: South Korea 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2015, 2025 & 2030
- TABLE 191: South Korea Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 192: South Korea Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 193: South Korea 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2015, 2025 & 2030
REST OF ASIA-PACIFIC
- TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 195: Rest of Asia-Pacific Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2015, 2025 & 2030
- TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 198: Rest of Asia-Pacific Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2015, 2025 & 2030
- TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 201: Rest of Asia-Pacific Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 202: Rest of Asia-Pacific 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2015, 2025 & 2030
LATIN AMERICA
- Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
- TABLE 203: Latin America Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 204: Latin America Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 205: Latin America 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2015, 2025 & 2030
- TABLE 206: Latin America Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 207: Latin America Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 208: Latin America 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2015, 2025 & 2030
- TABLE 209: Latin America Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 210: Latin America Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 211: Latin America 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2015, 2025 & 2030
- TABLE 212: Latin America Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 213: Latin America Historic Review for Point of Care (POC) Molecular Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 214: Latin America 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
ARGENTINA
- TABLE 215: Argentina Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 216: Argentina Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 217: Argentina 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2015, 2025 & 2030
- TABLE 218: Argentina Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 219: Argentina Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 220: Argentina 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2015, 2025 & 2030
- TABLE 221: Argentina Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 222: Argentina Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 223: Argentina 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2015, 2025 & 2030
BRAZIL
- TABLE 224: Brazil Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 225: Brazil Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 226: Brazil 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2015, 2025 & 2030
- TABLE 227: Brazil Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 228: Brazil Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 229: Brazil 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2015, 2025 & 2030
- TABLE 230: Brazil Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 231: Brazil Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 232: Brazil 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2015, 2025 & 2030
MEXICO
- TABLE 233: Mexico Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 234: Mexico Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 235: Mexico 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2015, 2025 & 2030
- TABLE 236: Mexico Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 237: Mexico Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 238: Mexico 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2015, 2025 & 2030
- TABLE 239: Mexico Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 240: Mexico Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 241: Mexico 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2015, 2025 & 2030
REST OF LATIN AMERICA
- TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 243: Rest of Latin America Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 244: Rest of Latin America 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2015, 2025 & 2030
- TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 246: Rest of Latin America Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 247: Rest of Latin America 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2015, 2025 & 2030
- TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 249: Rest of Latin America Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 250: Rest of Latin America 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2015, 2025 & 2030
MIDDLE EAST
- Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
- TABLE 251: Middle East Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 252: Middle East Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 253: Middle East 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2015, 2025 & 2030
- TABLE 254: Middle East Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 255: Middle East Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 256: Middle East 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2015, 2025 & 2030
- TABLE 257: Middle East Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 258: Middle East Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 259: Middle East 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2015, 2025 & 2030
- TABLE 260: Middle East Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 261: Middle East Historic Review for Point of Care (POC) Molecular Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 262: Middle East 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
IRAN
- TABLE 263: Iran Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 264: Iran Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 265: Iran 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2015, 2025 & 2030
- TABLE 266: Iran Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 267: Iran Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 268: Iran 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2015, 2025 & 2030
- TABLE 269: Iran Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 270: Iran Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 271: Iran 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2015, 2025 & 2030
ISRAEL
- TABLE 272: Israel Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 273: Israel Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 274: Israel 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2015, 2025 & 2030
- TABLE 275: Israel Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 276: Israel Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 277: Israel 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2015, 2025 & 2030
- TABLE 278: Israel Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 279: Israel Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 280: Israel 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2015, 2025 & 2030
SAUDI ARABIA
- TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 282: Saudi Arabia Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 283: Saudi Arabia 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2015, 2025 & 2030
- TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 285: Saudi Arabia Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 286: Saudi Arabia 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2015, 2025 & 2030
- TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 288: Saudi Arabia Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 289: Saudi Arabia 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2015, 2025 & 2030
UNITED ARAB EMIRATES
- TABLE 290: UAE Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 291: UAE Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 292: UAE 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2015, 2025 & 2030
- TABLE 293: UAE Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 294: UAE Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 295: UAE 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2015, 2025 & 2030
- TABLE 296: UAE Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 297: UAE Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 298: UAE 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2015, 2025 & 2030
REST OF MIDDLE EAST
- TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 300: Rest of Middle East Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 301: Rest of Middle East 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2015, 2025 & 2030
- TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 303: Rest of Middle East Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 304: Rest of Middle East 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2015, 2025 & 2030
- TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 306: Rest of Middle East Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 307: Rest of Middle East 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2015, 2025 & 2030
AFRICA
- Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
- TABLE 308: Africa Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 309: Africa Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 310: Africa 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2015, 2025 & 2030
- TABLE 311: Africa Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 312: Africa Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 313: Africa 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2015, 2025 & 2030
- TABLE 314: Africa Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 315: Africa Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 316: Africa 15-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2015, 2025 & 2030